METRIC: A randomized international study of the antibody drug conjugate (ADC) glembatumumab vedotin (GV, CDX-011) in patients (pts) with metastatic gpNMB overexpressing triple-negative breast cancer (TNBC)
Publication
, Conference
Schmid, P; Melisko, M; Yardley, DA; Blackwell, K; Forero, A; Ouellette, G; He, Y; Bagley, RG; Zhang, J; Vahdat, LT
Published in: Annals of Oncology
October 1, 2016
Duke Scholars
Published In
Annals of Oncology
DOI
EISSN
1569-8041
ISSN
0923-7534
Publication Date
October 1, 2016
Volume
27
Start / End Page
vi97
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Schmid, P., Melisko, M., Yardley, D. A., Blackwell, K., Forero, A., Ouellette, G., … Vahdat, L. T. (2016). METRIC: A randomized international study of the antibody drug conjugate (ADC) glembatumumab vedotin (GV, CDX-011) in patients (pts) with metastatic gpNMB overexpressing triple-negative breast cancer (TNBC). In Annals of Oncology (Vol. 27, p. vi97). https://doi.org/10.1093/annonc/mdw365.88
Schmid, P., M. Melisko, D. A. Yardley, K. Blackwell, A. Forero, G. Ouellette, Y. He, R. G. Bagley, J. Zhang, and L. T. Vahdat. “METRIC: A randomized international study of the antibody drug conjugate (ADC) glembatumumab vedotin (GV, CDX-011) in patients (pts) with metastatic gpNMB overexpressing triple-negative breast cancer (TNBC).” In Annals of Oncology, 27:vi97, 2016. https://doi.org/10.1093/annonc/mdw365.88.
Schmid P, Melisko M, Yardley DA, Blackwell K, Forero A, Ouellette G, et al. METRIC: A randomized international study of the antibody drug conjugate (ADC) glembatumumab vedotin (GV, CDX-011) in patients (pts) with metastatic gpNMB overexpressing triple-negative breast cancer (TNBC). In: Annals of Oncology. 2016. p. vi97.
Schmid, P., et al. “METRIC: A randomized international study of the antibody drug conjugate (ADC) glembatumumab vedotin (GV, CDX-011) in patients (pts) with metastatic gpNMB overexpressing triple-negative breast cancer (TNBC).” Annals of Oncology, vol. 27, 2016, p. vi97. Scopus, doi:10.1093/annonc/mdw365.88.
Schmid P, Melisko M, Yardley DA, Blackwell K, Forero A, Ouellette G, He Y, Bagley RG, Zhang J, Vahdat LT. METRIC: A randomized international study of the antibody drug conjugate (ADC) glembatumumab vedotin (GV, CDX-011) in patients (pts) with metastatic gpNMB overexpressing triple-negative breast cancer (TNBC). Annals of Oncology. 2016. p. vi97.
Published In
Annals of Oncology
DOI
EISSN
1569-8041
ISSN
0923-7534
Publication Date
October 1, 2016
Volume
27
Start / End Page
vi97
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis